Sarepta Therapeutics (SRPT) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 24.3% versus a loss of 22.1%. Over five years, XERS leads with a +409.5% price change compared with -78.4% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.92 billion vs $1.86 billion), about 1.0 times the size, while Xeris Biopharma is growing revenue faster (+43.7% vs +15.6%).
On valuation, Sarepta Therapeutics trades at a lower forward P/E (7.6x vs 27.5x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -32.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | XERS |
|---|---|---|
| Share price | $18.21 | $10.19 |
| Market cap | $1.92B | $1.86B |
| 1-day change | +4.06% | +0.79% |
| YTD return | -15.38% | +29.81% |
| 1-year return | -22.11% | +24.27% |
| 5-year return | -78.37% | +409.50% |
| Forward P/E | 7.55 | 27.54 |
| EPS (TTM) | $-1.57 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.20B | $291.85M |
| Revenue growth (YoY) | +15.58% | +43.72% |
| Net income (latest FY) | $-713.41M | $554.00K |
| Gross margin | 98.84% | 85.41% |
| Operating margin | -31.83% | 8.53% |
| Net margin | -32.45% | 0.19% |
| 52-week high | $24.68 | $11.33 |
| 52-week low | $14.68 | $5.25 |
| Distance from 52-week high | -26.22% | -10.06% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +19.33% | +26.20% |
| Average volume | 2.99M | 2.17M |
| Shares outstanding | 105.63M | 182.32M |
| Employees | 835 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed SRPT by 46.4 percentage points over the past year.
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -32.5 cents for Sarepta Therapeutics.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +15.58%).
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
SRPT vs XERS FAQ
Which is bigger, Sarepta Therapeutics or Xeris Biopharma?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.92B compared with $1.86B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, SRPT or XERS?
XERS returned +24.27% over the past 12 months, compared with -22.11% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.